SCHEMBL1640710

SCHEMBL1640710

CCCCNC(=O)c1c(O)c(C(=O)NCC(=O)O)c(=O)n(CC2CCCCC2)c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.45
EGLN3 Q9H6Z9 2/20 0.45
OGFOD1 Q8N543 1/20 0.45
EGLN2 Q96KS0 1/20 0.45
HIF1AN Q9NWT6 1/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
HIF1A Q16665 2/20 0.44
KDM4E B2RXH2 5/20 0.41
ALOX12 P18054 2/20 0.41
HTT P42858 1/20 0.41
KCNH2 Q12809 1/20 0.40
GSK3B P49841 1/20 0.39
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642373 0.88 CNR1 (0.48) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642306 0.86 EGLN1 (0.47) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642189 0.85 HIF1A (0.48) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1640775 0.83 EGLN1 (0.64) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642310 0.82 EGLN1 (0.61) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642198 0.80 EGLN1 (0.58) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1641951 0.76 KDM4E (0.49) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1641163 0.75 ALDH1A1 (0.39) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1641473 0.74 HIF1A (0.49) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1641965 0.74 EGLN3 (0.58) EGLN1EGLN3EGLN2KDM4EALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN1 6/4885EGLN3 3/4885OGFOD1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.